TRCT
FNCH

Tower Research Capital (TRC)’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Tower Research Capital (TRC)’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,163
Closed -$10.8K – 6198
2024
Q1 		$10.8K Buy
4,163
+1,537
+59% +$4.29K ﹤0.01% 3643
2023
Q4 		$9.48K Buy
2,626
+2,187
+498% +$8.63K ﹤0.01% 4381
2023
Q3 		$2.27K Sell
439
-218
-33% -$1.57K ﹤0.01% 5179
2023
Q2 		$5.6K Buy
657
+360
+121% +$3.69K ﹤0.01% 4810
2023
Q1 		$4K Sell
297
-121
-29% -$1.61K ﹤0.01% 5151
2022
Q4 		$6K Buy
+418
New +$14K ﹤0.01% 4808
2022
Q3 		– Sell
-11
Closed -$1K – 6769
2022
Q2 		$1K Sell
11
-100
-90% -$8.55K ﹤0.01% 5942
2022
Q1 		$17K Buy
111
+62
+127% +$14.3K ﹤0.01% 3730
2021
Q4 		$15K Buy
49
+21
+75% +$8.05K ﹤0.01% 4033
2021
Q3 		$11K Buy
28
+26
+1,300% +$11.1K ﹤0.01% 4280
2021
Q2 		$1K Buy
+2
New +$866 ﹤0.01% 5311

Other funds holding FNCH

LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Tower Research Capital (TRC)'s FNCH Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 4,163 shares — an estimated $10.8K sold.

Tower Research Capital (TRC) first reported a position in FNCH in Q2 2021 and held it in 11 quarters. The position peaked at $17K in Q1 2022. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,163 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $10.8K.
  • Tower Research Capital (TRC) first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Finch Therapeutics Group, Inc. Common Stock position peaked at $17K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.